Clinical trial
PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary…
NCT00455546 · Anthera Pharmaceuticals, Industry · Completed
Key facts
| NCT number | NCT00455546 |
|---|---|
| Title | PLASMA Trial: A Dose-Response Study of A-002 In Subjects With Stable Coronary Artery Disease |
| Official title | PLASMA Trial: Phospholipase Levels And Serological Markers of Atherosclerosis: A Dose-Response Clinical Pharmacology Study of A-002 In Subjects With Stable Coronary Artery Disease |
| Acronym | PLASMA |
| Lead sponsor | Anthera Pharmaceuticals, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Coronary Artery Disease (CAD) |
| Intervention type | Drug |
| Interventions | A-002 |
| Enrollment | 400 |
| Start date | Apr 1, 2007 |
| Completion | Sep 1, 2007 |
| First posted | Apr 3, 2007 |
| Last update posted | Feb 2, 2010 |
| Countries | Ukraine, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: